ClinicalTrials.gg
Status unknownNCT02479620LIMBO-ATXUpdated Feb 19, 2020

Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization

A Phase 2 interventional study of Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL in Chronic Limb Ischemia, sponsored by Mercator MedSystems, Inc.. Status unknown at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by Mercator MedSystems, Inc. · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 155 studies in Ischemia with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Ischemia · United States.

Planned enrollment
35th of 100
120 · median 60
Started
2016
with 6 others
Phase 2
24 of 155
none open now
Registered
104th of 155
by date

Among the 155 studies in Ischemia with a site in United States, this one is the 35th largest by planned enrollment of the 100 interventional ones that give a count, is one of 7 that started in 2016, is one of 24 in phase 2, and was the 104th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 71 are open to participants now.

Browse Ischemia studies →

Open to participants now

20 of the 155 studies in Ischemia with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Ischemia studies recruiting now, 34 (77%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies in Ischemia with a site in United States, or all of them as a file.
02

Study summary

This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI).

Read the detailed description

This is a prospective, multi-center, randomized pilot study to document the effects of adventitial delivery of dexamethasone after atherectomy-based revascularizations of lesions below the knee in symptomatic patients with critical limb ischemia (CLI). Up to 120 patients (60 treatment and 60 control), including up to 20 Rutherford 6 patients (10 treatment and 10 control) at up to 30 sites in the United States and Europe. This study will assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial deposition of dexamethasone in reducing inflammation and restenosis in patients with clinical evidence of chronic critical limb ischemia with an angiographically significant lesion in the infrapopliteal crural vessels.

03

Conditions studied

  • Chronic Limb Ischemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Screening Criteria:

  • Age ≥18 years
  • Patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an IRB/EC approved consent form
  • Female patients of have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of for the duration of study participation
  • Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb from the popliteal artery to the ankle joint prior to the study procedure with Rutherford Category 4, 5 or 6
  • >1 year in the Investigator's opinion

Angiographic Criteria:

  • Successful revascularization of the TL with less than 30% residual stenosis, run-off down to the foot and direct in-line flow to any foot wound
  • Reference vessel(s) diameter ≥2 mm
  • Single or multiple atherosclerotic lesion ≥70% in at least one infrapopliteal crural target vessel including the tibioperoneal trunk that totals up to 30 cm in length (with no greater than 5 cm length of contiguous intervening normal artery), with possible extension into the popliteal artery distal to the center of the knee joint space (the P3 segment)

Exclusion criteria

Exclusion Criteria:

Screening Criteria:

  • Patient unwilling or unlikely to comply with visit schedule
  • Planned major index limb amputation
  • Active foot infection; however, osteomyelitis in the toes or mild cellulitis around the perimeter of gangrene or small ulcers are not exclusions, but osteomyelitis of the metatarsal or more proximal region would be exclusionary
  • Inability to receive study medications
  • Estimated (eGFR) less than 30 mL/min, except for patients with end stage renal disease on chronic hemodialysis
  • Stage 3 (per SVS WIfI classification) or worse heel ulcers or heel ulcers that are determined to be primarily neuropathic in nature

Angiographic/Procedural Criteria:

  • Hemodynamically significant inflow lesion (≥50% DS) or occlusion in the ipsilateral iliac, SFA, or popliteal arteries in which there is failure to successfully treat and obtain a \<30% residual stenosis
  • Target lesion length is >25 cm as measured from proximal normal vessel to distal normal vessel
  • Total length of lesions treated during the case (including target lesion, inflow lesions, and other non-target lesions) >25 cm
  • Lesions revascularized during the index case but untreated by Bullfrog
  • Use of alternative therapy, e.g. radiation therapy, as part of the index lesion treatment, or use of any drug eluting stents (DES) or drug-eluting balloon/drug-coated balloons (DEB/DCB) for treatment of any infra-inguinal lesions during the study procedure or during the initial six-month follow up period
  • Previously implanted stent in the TL(s)
  • Aneurysm in the target vessel
  • Acute thrombus in the target limb
  • Failure to cross the TL with a guide wire; however, subintimal wire crossing is allowed
  • Heavy eccentric or concentric calcification at index lesion, which in the judgment of the investigator would prevent penetration of the Micro-Infusion Device needle through the vessel wall
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Dexamethasone Delivery

    Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe. For Subjects randomized into the Dexamethasone Delivery arm, this protocol will utilize a 4 mg/mL preparation of Dexamethasone Sodium Phosphate Injection, USP. Each milliliter of the solution contains 4.37 mg of dexamethasone sodium phosphate equivalent to 4 mg of dexamethasone phosphate or 3.33 mg of dexamethasone. The total dose of Dexamethasone Sodium Phosphate Injection, USP will be diluted by 20% prior to infusion. This will result in a final concentration of 3.2 mg dexamethasone phosphate (3.5 mg dexamethasone sodium phosphate, or 2.67 mg dexamethasone) in each milliliter of solution.

    Drug: Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL

  • No intervention
    Control

    Up to 60 atherectomy-based revascularization procedures at up to 30 sites in the United States and Europe. Standard endovascular revascularization therapy consisting of atherectomy with or without angioplasty and with or without stent placement. No additional drug will be given to Subjects randomized to Control.

Interventions

  • DrugDexamethasone Sodium Phosphate Injection, USP, 4 mg/mL

    Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.

06

What researchers measure

Primary outcomes

  1. Freedom from MALE

    Freedom from major adverse limb event (MALE) within 6 months.

    Time frame: Up to 6 Months following the procedure

  2. Freedom from CD-TLR

    Freedom from clinically driven target lesion revascularization (CD-TLR) within 6 months.

    Time frame: Up to 6 Months following the procedure

  3. Composite clinical safety by freedom from adverse events including death, MALE, major unplanned amputation, or CD-TLR.

    Freedom from composite of death within 30 days from the index procedure, MALE, major unplanned amputation or CD-TLR within 6 months.

    Time frame: Up to 6 Months following the procedure

  4. TVAL% change from post-procedure

    Transverse-view vessel area loss percentage (TVAL%) of the target lesion at 6 months by quantitative vascular angiography (QVA) or prior to any CD-TLR of the target lesion before 6 months

    Time frame: 6 Months following the procedure

Secondary outcomes

  1. Composite clinical safety by freedom from adverse events including death, unplanned amputation, CD-TLR, SAE or MALE.

    Freedom from composite of death, unplanned amputation and CD-TLR, serious adverse events (SAE) and MALE.

    Time frame: Up to 12 months following the procedure

  2. Event-free survival

    Proportion of patients reaching 12-month endpoint without a composite clinical safety event.

    Time frame: 12 months following the procedure

  3. QVA change from post-procedure

    Improvement in % diameter stenosis (%DSS) of the target lesion (TL) and the maximum late lumen loss for the lesion (LLL) will be assessed by quantitative vascular angiography (QVA).

    Time frame: 6 months following the procedure

  4. IVUS change from post-procedure

    Improvement in intravascular ultrasound (IVUS) result with in the TL (subgroup analysis).

    Time frame: 6 months following the procedure

  5. Amputation-free survival

    Percentage of patients reaching the endpoints without major or minor amputation.

    Time frame: 30 days, 6 and 12 months following the procedure

  6. Major and minor amputations and amputation level

    Percentage of patients requiring amputation (major: above ankle, minor: below ankle), categorized by level on the foot, ankle, or leg.

    Time frame: 30 days, 6 and 12 months following the procedure

  7. Change in foot wounds versus baseline

    The number and total size of foot wounds, reduction in number and size of baseline wounds, and occurrence of new wounds (number and size) will be measured against baseline.

    Time frame: 30 days, 6 and 12 Months following the procedure

  8. Resolved CLI death

    The rate of deaths in patients who had a resolution of their critical limb ischemia (CLI).

    Time frame: 30 days, 6 and 12 months following the procedure

  9. CD-TLR

    Time frame: 30 days, 6 and 12 months following the procedure

  10. Primary sustained clinical improvement versus baseline

    Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline without the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.

    Time frame: 30 days, 6 and 12 months following the procedure

  11. Secondary sustained clinical improvement versus baseline

    Sustained upward shift of at least 1 category on Rutherford classification as compared to baseline including the need for repeated TLR or surgical revascularization in amputation-free surviving subjects.

    Time frame: 30 days, 6 and 12 months following the procedure

  12. SVS WIfI score versus baseline

    Time frame: 30 days, 6 and 12 months following the procedure

  13. EQ5D versus baseline

    Time frame: 30 days, 6 and 12 months following the procedure

  14. Walking capacity assessment versus baseline

    Time frame: 30 days, 6 and 12 months following the procedure

  15. SAE/MALE assessment

    Time frame: 30 days, 6 and 12 months following the procedure

  16. Inflammatory biomarker changes from baseline

    Time frame: 24 hours and 30 days

  17. Healthcare economic analysis

    An analysis of the economics associated with the care of patients, including number of hospital days throughout the study, return visits and hospitalizations, time from index procedure to required revascularization and number of index-lesion-related readmissions.

    Time frame: From baseline to 24 months

  18. Infustion technical success

    The grade of distribution (A-F) around infusion sites will be used as a qualitative measure of technical success of adventitial delivery of the drug.

    Time frame: Intra-procedural

  19. Revascularization success

    Establishment of antegrade flow with residual stenosis \<30% by angiogram.

    Time frame: Intra-procedural

07

Study locations

10 sites
  • Arkansas Heart Hospital
    Little Rock, Arkansas 72211, United States
  • Denver Veterans Administration Hospital
    Denver, Colorado 80220, United States
  • Mid-Michigan Heart & Vascular
    Saginaw, Michigan 48604, United States
  • Hattiesburg Clinic
    Hattiesburg, Mississippi 39401, United States
  • St.Louis University Hospital
    Saint Louis, Missouri 63110, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • UNC Health Care - Rex Hospital
    Raleigh, North Carolina 27607, United States
  • Sanford Research
    Sioux Falls, South Dakota 57101, United States
  • Tennova - Turkey Creek Medical Center
    Knoxville, Tennessee 37934, United States
  • Mission Research Institute (New Braunfels Cardiology - GRMC)
    New Braunfels, Texas 78130, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Nov 2019, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2015
First posted
Jun 24, 2015
StartActual
Jun 2016
Primary completionActual
Nov 2019
CompletionEst.
Mar 2020
Last update
Feb 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02479620
Lead sponsor
Mercator MedSystems, Inc.
Responsible party
Sponsor
First posted
Jun 24, 2015
Start date
Jun 2016
Primary completion
Nov 2019
Completion
Mar 2020 (estimated)
Last update
Feb 19, 2020

Study contacts

George Adams, MD
principal investigator · REX Hospital, University of North Carolina Healthcare
Donald Jacobs, MD
principal investigator · Saint Louis University Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion